drugset / Trial / NCT07639086
Sacituzumab Tirumotecan in Pts w/ NEPC After Progression on Prior Chemotherapy
Phase 2
Not yet recruiting
20 enrolled
Virginia Commonwealth University
Merck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 2, open-label, single-arm study of sacituzumab tirumotecan in neuroendocrine prostate cancer (NEPC) with progression after platinum-based chemotherapy.
Timeline
- Start
- 2026-08-31
- Primary completion
- 2030-03-31
- Completion
- 2032-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sacituzumab Tirumotecan | Other / unclassified | 4 mg/kg | Intravenous |